Serious Infection Risk of Certolizumab vs. Other Therapies in Women with Psoriasis

Heber Rew Bright Bright published a document on figshare on 2026-05-12 under a CC-BY-4.0 license. The 971.2 KB DOCX file contains supporting information for a study comparing the serious infection risk of certolizumab to other systemic therapies in women with psoriasis. The specific data format and row count are unknown.

Use Cases

• Comparative drug safety analysis for biologics in psoriasis (inferred from domain, verify after download)
• Risk-benefit assessment for treatment selection in female patient populations (inferred from domain, verify after download)
• Supporting meta-analysis on infection risks associated with systemic psoriasis therapies (inferred from domain, verify after download)

Strengths

• Published on figshare with a permissive CC-BY-4.0 license.
• File size is 971.2 KB, indicating a focused document.

Limitations

• Metadata is minimal; actual content requires verification after download.
• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.

Provenance

Source

Heber Rew Bright Bright

Freshness

Last updated 2026-05-12 07:17:31; freshness should be verified.